Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of @entity1 with XXXX .

@entity1 @entity625 @entity571 @entity4047 @entity1421 @entity20447 @entity53099 @entity13695 @entity309
OBJECTIVE: To evaluate the role of an antiinflammatory lipid mediator, lipoxin A4 ( @entity20447 ), in @entity625 , we measured the level of @entity20447 in synovial fluid and lipoxin A4 receptor ( @entity53099 ) expression in synovial tissues obtained from @entity1 with @entity309 ( @entity309 ) and @entity571 ( @entity571 ). METHODS: Levels of @entity20447 and its analog ( @entity20447 ) in synovial fluid from 30 @entity1 with @entity309 and 15 @entity1 with @entity571 were measured by a specific ELISA. Reverse transcription-polymerase chain reaction (RT-PCR), real-time quantitative PCR, and in situ hybridization were performed to detect mRNA for @entity53099 and @entity13695 , and @entity20447 synthetase, in synovial tissues from 20 @entity1 with @entity309 and 10 @entity1 with @entity571 . RESULTS Both @entity20447 and @entity20447 showed significantly higher levels in @entity309 synovial fluid (10.34 +/- 14.12 ng/ml for @entity20447 ) than @entity571 synovial fluid (0.66 +/- 0.77 ng/ml for @entity20447 ). Logarithmic concentration of @entity20447 was significantly correlated with that of leukotriene B4 and @entity1421 in @entity309 and @entity571 synovial fluids. Expressions of @entity53099 and @entity13695 mRNA were stronger in @entity309 synovium than @entity571 synovium. Expression of mRNA for @entity4047 ( @entity4047 ), which induces @entity13695 , was significantly stronger in @entity309 synovium than @entity571 synovium. CONCLUSION: @entity53099 is an important target of @entity20447 in synovial tissues of @entity1 with @entity309 . @entity13695 induced by @entity4047 might regulate the production of @entity20447 to have an antiinflammatory effect against proinflammatory lipid mediators in inflamed joints. These findings could lead to the development of new therapy for @entity625 such as @entity309 .
